Hossein Borghaei

Hossein Borghaei

UNVERIFIED PROFILE

Are you Hossein Borghaei?   Register this Author

Register author
Hossein Borghaei

Hossein Borghaei

Publications by authors named "Hossein Borghaei"

Are you Hossein Borghaei?   Register this Author

83Publications

3063Reads

11Profile Views

Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).

Cancer 2020 Jan 6;126(2):260-270. Epub 2019 Nov 6.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32468DOI Listing
January 2020

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

N Engl J Med 2019 11 28;381(21):2020-2031. Epub 2019 Sep 28.

From the Memorial Sloan Kettering Cancer Center, New York (M.D.H.); Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and Centro de Investigación Biomédica en Red de Cáncer, Madrid (L.P.-A.), Hospital Universitario Virgen Del Rocio, Seville (R.B.C.), and the Catalan Institute of Oncology-Germans Trias i Pujol Hospital, Badalona (E.C.C.) - all in Spain; Ambulatorium Chemioterapii, Bydgoszcz, Poland (B.Z.); the Asan Medical Center (S.-W.K.) and the Samsung Medical Center at Sungkyunkwan University School of Medicine (K.P.) - both in Seoul, South Korea; the Institute of Oncology Prof. Dr. Alexandru Trestioreanu, Bucharest, Romania (A.A.); the Hospital Italiano de Buenos Aires, Buenos Aires (L.L.); Instituto Jalisciense de Cancerologia, Guadalajara, Mexico (E.M.J.); the Saitama Cancer Center, Saitama, Japan (H.S.); Matrai Gyogyintezet, Matrahaza, Hungary (I.A.); Limoges University Hospital, Limoges (A.V.), and Aix-Marseille University, National Center for Scientific Research, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.) - all in France; Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland (S.P.); Sotiria General Hospital, National and Kapodistrian University of Athens, Athens (K.S.); Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany (M.R.); Fox Chase Cancer Center, Philadelphia (H.B.); Johns Hopkins Kimmel Cancer Center, Baltimore (J.R.B.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., P.B., S.K.R., R.S.K., F.E.N.); and Winship Cancer Institute, Emory University, Atlanta (S.S.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910231DOI Listing
November 2019

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.

Adv Ther 2019 Oct 13;36(10):2638-2678. Epub 2019 Aug 13.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-01051-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778545PMC
October 2019

Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.

Cancer Treat Res Commun 2019 26;19:100126. Epub 2019 Feb 26.

Lineberger Cancer Center at the University of North Carolina, 170 Manning Drive, Room 3115, Campus Box 7305, Chapel Hill, NC 27514, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100126DOI Listing
September 2019

Nivolumab plus ipilimumab in non-small-cell lung cancer.

Future Oncol 2019 Jul 8;15(19):2287-2302. Epub 2019 May 8.

Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, QLD 4102, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0031DOI Listing
July 2019

First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.

J Oncol Pract 2018 09;14(9):529-535

Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.18.00250
Publisher Site
http://dx.doi.org/10.1200/JOP.18.00250DOI Listing
September 2018

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Cancer Cell 2018 05 12;33(5):843-852.e4. Epub 2018 Apr 12.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 885 2(nd) Avenue, New York, NY 10017, USA; Weill Cornell School of Medicine, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183012
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953836PMC
May 2018

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

N Engl J Med 2018 May 16;378(22):2093-2104. Epub 2018 Apr 16.

From Memorial Sloan Kettering Cancer Center Hospital, New York (M.D.H.); Prof. Dr. Ion Chiricuta Institute of Oncology and Universitatea de Medicina si Farmacie Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland (A.P.); Seoul National University Bundang Hospital, Seoul, South Korea (J.S.L.); Ohio State University, Columbus (G.A.O.); Hôpital Sainte Musse, Toulon, France (C.A.-V.); Ospedale Santa Maria della Misericordia, Perugia, Italy (E.M.); First Department of Oncology, Metropolitan Hospital, Athens, Greece (H.L.); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (S.B.); Fundación Arturo López Pérez, Santiago, Chile (P.S.); Fox Chase Cancer Center, Philadelphia (H.B.); Winship Cancer Institute, Emory University, Atlanta (S.S.R.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.B.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany (M.R.); Princess Alexandra Hospital, Brisbane, QLD, Australia (K.J.O.); Bristol-Myers Squibb, Princeton, NJ (W.J.G., G.G., H.C., J.S., P.B., D.H., Y.F., F.N.); and Hospital Universitario 12 de Octubre, Centro Nacional de Investigaciones Oncológicas, Universidad Complutense, and CiberOnc, Madrid (L.P.-A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1801946DOI Listing
May 2018

Managing adverse effects of immunotherapy.

Clin Adv Hematol Oncol 2018 May;16(5):364-374

Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
May 2018

"My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now?" Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC.

Am Soc Clin Oncol Educ Book 2018 May;38:696-707

From the Sarah Cannon Research Institute, Nashville, TN; Cleveland Clinic, Cleveland, OH; Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201231DOI Listing
May 2018

Immunotherapy of lung cancer.

J Thorac Dis 2018 Feb;10(Suppl 3):S395-S396

Associate Guest Editor, Associate Professor, Chief, Thoracic Oncology, Department of Medicine, Fox Chase Cancer Center/Temple University, Philadelphia, PA, USA. (Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.01.142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861270PMC
February 2018

Identifying and managing the adverse effects of immune checkpoint blockade.

J Thorac Dis 2018 Feb;10(Suppl 3):S480-S489

Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.01.111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861268PMC
February 2018

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

J Clin Oncol 2017 Dec 12;35(35):3924-3933. Epub 2017 Oct 12.

Leora Horn, Vanderbilt-Ingram Cancer Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Everett E. Vokes, University of Chicago, Chicago, IL; Esther Holgado, Hospital De Madrid, Norte Sanchinarro, Madrid; Enriqueta Felip, Hospital Universitari Vall d'Hebron, Barcelona; Luis Paz-Ares, Hospital Universitario Virgen Del Rocio, Seville, Spain; Neal Ready, Duke University Medical Center, Durham, NC; Martin Steins, Thoraxklinik-Heidelberg gGmbH, Heidelberg; Martin Kohlhäeufl, Robert-Bosch-Krankenhaus, Stuttgart; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Wilfried E.E. Eberhardt, University Hospital and Ruhrlandclinic, University of Duisburg-Essen, Essen, Germany; Elena Poddubskaya, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Adam Pluzanski, Centrum Onkologii-Instytut Im. Marii Sklodowskiej-Curie, Warsaw, Poland; Karen L. Reckamp, City of Hope, Duarte, CA; Marco A. Burgio and Lucio Crinò, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico Romagnolo Per lo Studio e la Cura dei Tumori, Meldola, Italy; David Waterhouse, Oncology Hematology Care (OHC)/US Oncology, Cincinnati, OH; Fabrice Barlesi, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Marseille; Jérôme Fayette, Léon Bérard, Lyon, France; Scott Antonia, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Oscar Arrieta, Instituto Nacional De Cancerologia, Mexico City, Mexico; Naiyer Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; William J. Geese, Ang Li, Anne Blackwood-Chirchir, and Diane Healey, Bristol-Myers Squibb, Princeton, NJ; and Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.3062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075826PMC
December 2017

Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.

Clin Lung Cancer 2017 11 26;18(6):640-650.e2. Epub 2017 Apr 26.

Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.04.010DOI Listing
November 2017

Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.

Am J Clin Oncol 2017 Aug;40(4):329-335

Departments of *Medicine, Division of Hematology/Oncology #Pathology and Laboratory Medicine ††Biostatistics, Indiana University School of Medicine †Indiana University Melvin and Bren Simon Cancer Center, Indianapolis ¶Cancer Care Center of Southern Indiana, Bloomington ‡Northern Indiana Cancer Research Consortium, South Bend, IN §Christiana Care Health Services, Newark, DE ∥Fox Chase Cancer Center, Philadelphia, PA **The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000160DOI Listing
August 2017

Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.

Oncologist 2017 06 13;22(6):700-708. Epub 2017 Apr 13.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469580PMC
June 2017

Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?

Curr Treat Options Oncol 2017 06;18(6):33

Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-017-0476-yDOI Listing
June 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

N Engl J Med 2017 06;376(25):2415-2426

From the Ohio State University Comprehensive Cancer Center, Columbus (D.P.C.); LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.), and Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) - both in Germany; Hospital Universitario Doce de Octubre, Centro Nacional de Investigaciones Oncológicas and Universidad Complutense, Madrid (L.P.-A., J.C.J.), Vall d'Hebron University Hospital, Barcelona (E.F.), and Hospital Universitario Insular de Gran Canaria, Las Palmas (D.R.-A.) - all in Spain; H. Lee Moffitt Cancer Center, Tampa, FL (B.C.); Vanderbilt University Medical Center, Nashville (L. Horn); Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (M.M.H.), and University of Groningen, Universitair Medisch Centrum Groningen, Groningen (T.J.N.H.) - both in the Netherlands; Prof. Dr. Ion Chiricuta Institute of Oncology and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania (T.-E.C.); Baptist Health Lexington, Lexington, KY (F.B.); Duke University, Durham, NC (N.R.); Lehigh Valley Health Network, Allentown (S.N.), Fox Chase Cancer Center, Philadelphia (H.B.), and University of Pittsburgh Medical Center Cancer Center, Pittsburgh (L.C.V., M.A.S.) - all in Pennsylvania; Juravinski Cancer Centre, Hamilton, ON, Canada (R.J.); Oncology Department, Lausanne University Hospital, Lausanne, Switzerland (S.P.); Santa Maria Hospital, Terni, Italy (E.M.); Hollings Cancer Center, Charleston, SC (J.M.W.); Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); Klinika Pneumologie a Hrudní Chirurgie, Nemocnice Na Bulovce, Prague, Czech Republic (L. Havel, J.K.); and Bristol-Myers Squibb, Princeton, NJ (H.C., W.J.G., P.B., A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310PMC
June 2017

Low Level of Blood CD4 T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2017 02 30;17(2):83-88. Epub 2016 Nov 30.

Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.11.005DOI Listing
February 2017

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2969-79. Epub 2016 Jun 27.

Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Julie R. Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Scott Gettinger, Yale Cancer Center, New Haven, CT; Laura Q. Chow, University of Washington, Seattle, WA; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; Allen C. Chen, Yun Shen, Faith E. Nathan, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ; and Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.66.9861
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.66.9861DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569693PMC
September 2016

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 09 27;34(25):2980-7. Epub 2016 Jun 27.

Scott Gettinger, Yale Cancer Center, New Haven, CT; Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; Laura Q. Chow, University of Washington, Seattle, WA; Hossein Borghaei, Fox Chase Cancer Center, Philadelphia, PA; Julie Brahmer, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Neal Ready, Duke University Medical Center, Durham, NC; David E. Gerber, University of Texas Southwestern Medical Center, Dallas, TX; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto; Rosalyn A. Juergens, Juravinski Cancer Centre at McMaster University, Hamilton; Scott A. Laurie, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Scott Antonia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Jonathan W. Goldman, University of California, Los Angeles, Los Angeles, CA; and Faith E. Nathan, Yun Shen, and Christopher T. Harbison, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569692PMC
September 2016

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

J Natl Compr Canc Netw 2016 07;14(7):825-36

From The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; City of Hope Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Mayo Clinic Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0087DOI Listing
July 2016

Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.

Proc Natl Acad Sci U S A 2016 06 6;113(25):6955-60. Epub 2016 Jun 6.

Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, 19111; Department of Medical Oncology, University of New Mexico Cancer Center, Albuquerque, NM 87131; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1513616113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922167PMC
June 2016

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

N Engl J Med 2016 02;374(5):493-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1514790DOI Listing
February 2016

Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2016 Jan 30;17(1):1-9. Epub 2015 Jul 30.

Eli Lilly and Company, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.07.002DOI Listing
January 2016

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

N Engl J Med 2015 Oct 27;373(17):1627-39. Epub 2015 Sep 27.

From the Fox Chase Cancer Center, Philadelphia (H.B.); Hospital Universitario Virgen del Rocio, Seville (L.P.-A.), Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.), and Hospital de Madrid, Norte Sanchinarro, Madrid (E.H.) - all in Spain; Vanderbilt-Ingram Cancer Center (L.H.), and Sarah Cannon Research Institute and Tennessee Oncology (D.R.S.) - both in Nashville; Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.) and Robert-Bosch-Krankenhaus Stuttgart, Gerlingen (M.K.) - both in Germany; Duke University Medical Center, Durham, NC (N.E.R.); University of Washington, Seattle (L.Q.C.); University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille (F.B.), Centre Léon Bérard, Lyon (J.F.), and Centre Hospitalier Universitaire de Rennes, Rennes (H.L.) - all in France; Instituto Nacional de Cancerologia, Mexico City (O.A.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Forlì-Cesena (M.A.B.), and Ospedale di Perugia, Perugia (L.C.) - both in Italy; N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); University of Texas Southwestern Medical Center, Dallas (D.E.G.); Yale Comprehensive Cancer Center, New Haven, CT (S.N.G.); Memorial Sloan Kettering Cancer Center, New York (C.M.R., N.R.); University of Texas M.D. Anderson Cancer Center, Houston (G.R.B.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.J.A.); Bristol-Myers Squibb, Princeton, NJ (C.D., C.T.H., F.G.F.); and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.R.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1507643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705936PMC
October 2015

Non-Small Cell Lung Cancer, Version 6.2015.

J Natl Compr Canc Netw 2015 May;13(5):515-24

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Washington/Seattle Cancer Care Alliance; Huntsman Cancer Institute at the University of Utah; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; University of Colorado Cancer Center; Roswell Park Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; Duke Cancer Institute; Moffitt Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; City of Hope Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; University of Michigan Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Mayo Clinic Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0071DOI Listing
May 2015

Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery.

Cancer Control 2014 Jan;21(1):57-62

Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/107327481402100108DOI Listing
January 2014

Personalized medicine and treatment approaches in non-small-cell lung carcinoma.

Pharmgenomics Pers Med 2012 25;5:113-23. Epub 2012 Sep 25.

Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PGPM.S24258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513233PMC
April 2013

A rapid method to regenerate piezoelectric microcantilever sensors (PEMS).

Sensors (Basel) 2011 ;11(5):5520-8

Developmental Therapeutics Program, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148522PMC
http://dx.doi.org/10.3390/s110505520DOI Listing
June 2012

Mesothelin, a novel immunotherapy target for triple negative breast cancer.

Breast Cancer Res Treat 2012 Jun 15;133(2):799-804. Epub 2012 Mar 15.

Division of Endocrine and Oncologic Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-1693, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2018-4
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2018-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964602PMC
June 2012

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

J Clin Oncol 2010 Aug 12;28(23):3701-8. Epub 2010 Jul 12.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.27.2377DOI Listing
August 2010

Naptumomab estafenatox: a new immunoconjugate.

Expert Opin Biol Ther 2010 Feb;10(2):273-9

Fox Chase Cancer Center, Department of Medical Oncology, 333 Cottman Ave, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712590903575620DOI Listing
February 2010

Immunotherapy of cancer.

Eur J Pharmacol 2009 Dec 20;625(1-3):41-54. Epub 2009 Oct 20.

Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S001429990900890
Publisher Site
http://dx.doi.org/10.1016/j.ejphar.2009.09.067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783916PMC
December 2009

Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer.

Clin Lung Cancer 2009 Nov;10(6):438-40

Department of Hematology and Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2009.n.082DOI Listing
November 2009

Rational use of cetuximab in the treatment of advanced non-small cell lung cancer.

Onco Targets Ther 2009 Feb 18;2:251-60. Epub 2009 Feb 18.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886327PMC
http://dx.doi.org/10.2147/ott.s4761DOI Listing
February 2009

Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer.

Future Oncol 2009 Feb;5(1):19-22

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/14796694.5.1.19
Publisher Site
http://dx.doi.org/10.2217/14796694.5.1.19DOI Listing
February 2009

Targeted therapies in solid tumors: monoclonal antibodies and small molecules.

Hum Antibodies 2006 ;15(3):103-11

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
January 2007

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature.

Leuk Res 2006 Jan 25;30(1):109-14. Epub 2005 Jul 25.

Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S014521260500207
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2005.05.017DOI Listing
January 2006

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.

Cancer 2004 Nov;101(9):2034-41

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20616DOI Listing
November 2004

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Semin Nucl Med 2004 Jan;34(1 Suppl 1):4-9

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semnuclmed.2003.11.002DOI Listing
January 2004